Monday, May 20, 2013

• Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical CompanyPR Newswire( (Mon, May 20)

Tuesday, May 14, 2013

• Announcement Under Irish Takeover Rules Relevant Securities in IssuePR Newswire( (Tue, May 14)

Monday, May 13, 2013

• Actavis' NDA for Progestin-Only Patch Accepted for Filing by FDAPR Newswire( (Mon, May 13)
• Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare ConferencePR Newswire( (Mon, May 13)

Friday, May 10, 2013

• Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plcPR Newswire( (Fri, May 10)

Thursday, May 9, 2013

• Actavis Confirms District Court Ruling In Generic Lialda® Patent SuitPR Newswire( (Thu, May 9)

Tuesday, May 7, 2013

• Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care ConferencePR Newswire( (Tue, May 7)

Friday, May 3, 2013

• Actavis to Host Annual Meeting of Stockholders on May 10, 2013PR Newswire( (Fri, May 3)

Thursday, May 2, 2013

• Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 BillionPR Newswire( (Thu, May 2)

Wednesday, May 1, 2013

• Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal GelCNW Group( (Wed, May 1)
• Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal GelPR Newswire( (Wed, May 1)
• Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal GelPR Newswire( (Wed, May 1)